Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

Pharmala Biotech Holdings  / Equity Bottom-Up

<ul><li>FDA’s first-ever priority vouchers send out positive signals for psychedelics.</li><li>Following up on our podcast discussion with Kadysh in June about the FDA’s proposed reforms, including the idea of a national priority voucher program, he highlighted the recent award of the first-ever priority vouchers to nine products, which included ketamine (a psychedelic-like compound) for US manufacturing.</li><li>This means that anyone who applies to the FDA to manufacture ketamine in the US (currently approved for the treatment of treatment-resistant depression under the brand Spravato®) gets an “incredibly aggressive” two-month review timeline. </li></ul>

FDA’s first-ever priority vouchers send out positive signals for psychedelics.Following up on our podcast discussion with Kadysh in June about the FDA’s proposed reforms, including the idea of a national priority voucher program, he highlighted the recent award of the first-ever priority vouchers to nine products, which included ketamine (a psychedelic-like compound) for US manufacturing.This means that anyone who applies to the FDA to manufacture ketamine in the US (currently approved for the treatment of treatment-resistant depression under the brand Spravato®) gets an “incredibly aggressive” two-month review timeline. 

Psychedelics, the FDA, and PharmAla's Strategic Approach Post-Lykos CRL